Clear Scientific News

Cambridge, MA | August 2026 Clear Scientific, a clinical-stage biopharmaceutical company, was awarded a $5.2M award from the NIH’s National Institute on Drug Abuse to continue the development of CS-1103 through Phase 2 clinical trials for the reversal of methamphetamine intoxication. Illicit stimulant use, especially methamphetamine, is a major public health crisis for which there are no FDA-approved therapeutics. Clear Scientific has raised an additional $2.6M in an open SA

Cambridge MA | Sept 2024 Clear Scientific, a clinical-stage biopharmaceutical company, today announced a $3M award from the National Institute on Drug Abuse of the NIH to support continued development of its candidate sequestrant-based therapeutic to reverse overdose from combinations of fentanyl and xylazine. The therapeutic immediately inactivates fentanyl and xylazine by binding and encapsulation, rapidly reversing their toxic effects, and accelerates their clearance from

Cambridge, MA | Nov 2023 Clear Scientific, a clinical-stage biopharmaceutical company, today announced an award from the National Institute on Drug Abuse (NIDA) of the NIH, with a total potential value of $15M, to support development of CS-1103, the first therapeutic that both rapidly deactivates and removes fentanyl from the body. Fentanyl misuse is a nationwide crisis, with over 1M emergency department visits and 73,000 overdose deaths annually. There are substantial defic

Cambridge, MA | Nov 2023 Clear Scientific, a clinical-stage biopharmaceutical company, today announced a $12M award from the National Institute on Drug Abuse of the NIH to support development of CS-1103, an antidote for methamphetamine overdose, through Phase 2 clinical trials. This is the first step in our development of a broad-spectrum antidote for illicit and prescription stimulants. Stimulant misuse is a major worldwide public health crisis for which there are no FDA-ap

Cambridge, Massachusetts | February 2022 Opioid use in the context of polysubstance use (i.e., co-use of two or more illicit substances) is common and further exacerbates the problem of treating acute opioid overdose. Clear Scientific Inc. has received a grant from NIDA to develop a broad-spectrum antidote against acute intoxication caused by the most prevalent drugs of abuse.

Cambridge, Massachusetts | August 2021 Clear Scientific received an award to develop a stable, multidose vial (MDV) formulation of scopolamine. Scopolamine can be used as a life-saving therapeutic to treat acute nerve agent poisoning, and a stable MDV formulation will allow for application of the medical countermeasure in the field and in situations where multiple doses need to be quickly distributed to affected civilians or warfighters. CSInc will aim to develop a stable and

Cambridge, Massachusetts | January 2021 Clear Scientific, Inc (CSInc) is excited to announce continued support from government agencies on the development of life-saving medical countermeasures against chemical threats. CSInc is currently developing an engineered variant of a human enzyme called butyrylcholinesterase (BChE). This enzyme can directly neutralize nerve agent within the body, preventing serious injury or death to the warfighter. The development of this drug compl

Cambridge, Massachusetts | October 2020 Clear Scientific Inc. receives $12MM grant from the National Institute on Drug Abuse (NIDA) to develop an antidote against acute intoxication from methamphetamine. The U01 grant is under NIDA’s Grand Opportunity in Medications Development for Substance Use Disorders program. Clear Scientific completed a successful proof-of-concept preclinical study with the antidote. The heart of Clear Scientific's mission is saving lives. Clear Scienti

Cambridge, Massachusetts | October 2020 Clear Scientific Inc. receives grant from NIDA to develop an antidote against acute intoxication from fentanyl and its derivatives. The heart of Clear Scientific's mission is saving lives. Clear Scientific is developing a family of technologies that identify, neutralize, and eliminate harmful compounds to treat life-threatening conditions using our novel chemistry platform. We are creating new countermeasures to mitigate chemical